NCT04710576 2026-03-16AGAVE-201Syndax PharmaceuticalsPhase 2 Active not recruiting241 enrolled 11 charts 1 FDA
NCT03238027 2024-05-17A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid TumorsSyndax PharmaceuticalsPhase 1 Completed45 enrolled